#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3698	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2605	419.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1667	1667	C	484	C,T	419,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4031	418.4	0	.	n	.	0	T695C	SNP	695	695	T	1197	1197	C	457	C,T	407,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4031	418.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1839	1839	A	492	A	452	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4031	418.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2473	2473	C	471	C,A	433,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4031	418.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2547	2547	A	508	A	453	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4031	418.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3099	3099	C	488	C,T,A,G	426,3,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	852	folP	852	852	100.0	folP.l6.c17.ctg.1	1957	130.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1252	1254	AGC	189;191;192	A;G;C	168;173;168	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1486	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4192	106.3	1	SNP	p	S91F	0	.	.	271	273	TCC	1104	1106	TCC	159;157;156	T,C,A;C,A;C	136,1,1;136,1;141	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1486	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4192	106.3	1	SNP	p	D95G	0	.	.	283	285	GAC	1116	1118	GAC	151;153;153	G;A;C	138;137;137	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1486	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4192	106.3	1	SNP	p	D95N	0	.	.	283	285	GAC	1116	1118	GAC	151;153;153	G;A;C	138;137;137	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	628	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1804	104.5	0	.	p	.	0	A40P	NONSYN	118	120	GCC	711	713	CCC	156;155;155	C,T;C;C	144,1;142;144	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	628	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1804	104.5	1	SNP	p	G45D	0	.	.	133	135	GGC	726	728	GGC	153;153;154	G;G;C	146;142;147	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1580	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3523	134.2	1	SNP	p	D86N	0	.	.	256	258	GAC	879	881	GAC	159;159;158	G;A,C;C,T	140;135,2;142,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1580	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3523	134.2	1	SNP	p	S87R	0	.	.	259	261	AGT	882	884	AGT	158;159;159	A;G;T	137;146;138	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1580	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3523	134.2	1	SNP	p	S87W	0	.	.	259	261	AGT	882	884	AGT	158;159;159	A;G;T	137;146;138	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1580	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3523	134.2	1	SNP	p	S87I	0	.	.	259	261	AGT	882	884	AGT	158;159;159	A;G;T	137;146;138	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1580	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3523	134.2	1	SNP	p	S88P	0	.	.	262	264	TCC	885	887	TCC	160;161;161	T;C;C	143;148;151	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1424	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3227	132.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1877	1879	GGC	165;164;163	G;G;C,A	154;148;146,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1396	1398	GCA	157;157;159	G;C;A	136;139;141	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1399	1401	ATC	159;159;158	A;T;C	145;143;146	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1411	1413	GTG	164;166;169	G;T;G	152;152;154	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1411	1413	GTG	164;166;169	G;T;G	152;152;154	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1915	1917	ACC	152;153;153	A,C;C;C	140,1;134;137	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1969	1971	GCG	147;148;148	G;C;G	130;123;126	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1969	1971	GCG	147;148;148	G;C;G	130;123;126	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2092	2094	GGC	140;139;139	G,C;G,T;C	120,2;123,1;124	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2101	2103	GGC	137;136;136	G,T,C;G;C	118,1,1;118;121	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1116	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2791	119.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2119	2121	CCG	135;135;136	C;C;G	117;124;122	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1336	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3455	115.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1779	1781	CTG	147;147;147	C;T;G	129;118;121	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	778	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2474	94.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	893	893	C	140	C	127	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	949	951	CTT	131;133;134	C,G;T,G;T,G	118,1;116,1;119,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	973	975	GGA	133;133;132	G,A,C,T;G,A;A	118,2,1,1;123,1;122	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1057	1059	GGT	133;133;133	G;G,A;T,C	120;121,2;122,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1111	1113	AGC	142;143;144	A;G,A,T;C	123;124,1,1;129	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1177	1177	T	135	T,G	123,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	1	SNP	p	G120K	0	.	.	358	360	GGT	904	906	GGT	148;148;147	G,A;G,A;T,G	134,1;129,1;129,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	1	SNP	p	A121D	0	.	.	361	363	GCC	907	909	GCC	147;146;147	G,A;C,A;C,T	127,1;130,1;131,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	748	porB1b	1035	1035	95.82	porB1b.l6.c30.ctg.1	2200	101.0	1	SNP	p	A121N	0	.	.	361	363	GCC	907	909	GCC	147;146;147	G,A;C,A;C,T	127,1;130,1;131,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1922	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5521	104.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2352	2354	AAT	126;126;127	A;A;T,G	112;113;115,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	186	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1554	35.8	1	SNP	p	V57M	1	.	.	169	171	ATG	833	835	ATG	71;71;71	A;T;G	64;62;64	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
